XFLH Capital enters business combination with Renogen Biolab
- XFLH Capital (XFLH) signed a non-binding letter of intent to combine with Renogen Biolab Inc., a Canadian health service provider.
- Under the proposed transaction, the companies will work in good faith to negotiate definitive agreements and aim to execute them as soon as practicable.
- Renogen Biolab provides molecular capabilities including DNA services, vector engineering, and protein expression.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.